Cancer of the Peripheral Nerve in Neurofibromatosis Type 1

Research output: Contribution to journalReview articlepeer-review

Abstract

The RASopathy neurofibromatosis 1 is an autosomal dominant hereditary cancer syndrome that represents a major risk for the development of malignancies, particularly malignant peripheral nerve sheath tumors (MPNSTs). MPNSTs are unique sarcomas that originate from the peripheral nerve and represent the only primary cancer of the peripheral nervous system. To date, surgery is the only treatment modality proven to have survival benefit for MPNSTs and even when maximal surgery is feasible, these tumors are rarely curable, despite the use of chemotherapy and radiation. In this review, we discuss the current state-of-the-art treatments for MPNSTs, latest therapeutic developments, and critical aspects of the underlying molecular and pathophysiology that appear promising for therapeutic developments in the future. In particular, we discuss the specific elements of cancer in the peripheral nerve and how that may impel development of unique therapies for this form of sarcoma.

Original languageEnglish (US)
Pages (from-to)298-306
Number of pages9
JournalNeurotherapeutics
Volume14
Issue number2
DOIs
StatePublished - Apr 1 2017

Keywords

  • Chemoprevention
  • Malignant peripheral nerve sheath tumor
  • Malignant transformation
  • Neurofibromatosis
  • Sarcoma
  • Treatment

ASJC Scopus subject areas

  • Pharmacology
  • Clinical Neurology
  • Pharmacology (medical)

Fingerprint

Dive into the research topics of 'Cancer of the Peripheral Nerve in Neurofibromatosis Type 1'. Together they form a unique fingerprint.

Cite this